Naveen Reddy

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Induced Pluripotent Stem Cells

Tyrosine Kinase

Metastatic Breast Cancer

Epidermal Growth Factor Receptor

Top Venues

JCO global oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Naveen Reddy, Pramod Reddy, Ankit Ranpura, Narendra Maharaj, Rajendersingh Arora, Gopichand Mamillapalli, Aditya Shirish Adhav, Ashok Kumar Diwan, Alexey Manikhas, Dmitriy Krasnozhon
Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Randomized Controlled Trial. JCO global oncology 10 (2024)
Naveen Reddy, Pramod Reddy, Ankit Ranpura, Narendra Maharaj, Rajendersingh Arora, Gopichand Mamillapalli, Aditya Shirish Adhav, Ashok Kumar Diwan, Alexey Manikhas, Dmitriy Krasnozhon
Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Randomized Controlled Trial. JCO global oncology 10 (2024)
Naveen Reddy, Pramod Reddy, Ankit Ranpura, Narendra Maharaj, Rajendersingh Arora, Gopichand Mamillapalli, Aditya Shirish Adhav, Ashok Kumar Diwan, Alexey Manikhas, Dmitriy Krasnozhon
Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Randomized Controlled Trial. JCO global oncology 10 (2024)
Naveen Reddy, Pramod Reddy, Ankit Ranpura, Narendra Maharaj, Rajendersingh Arora, Gopichand Mamillapalli, Aditya Shirish Adhav, Ashok Kumar Diwan, Alexey Manikhas, Dmitriy Krasnozhon
Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Randomized Controlled Trial. JCO global oncology 10 (2024)